CellSource Co., Ltd. (4880.T)
JPY 844.0
(-1.97%)
JPY 844.0
(-1.97%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 3.18 Billion JPY | 3.94% |
| 2022 | 3.06 Billion JPY | 47.75% |
| 2021 | 2.07 Billion JPY | 64.74% |
| 2020 | 1.25 Billion JPY | 9.13% |
| 2019 | 1.15 Billion JPY | 31.7% |
| 2018 | 875.92 Million JPY | 192.05% |
| 2017 | 299.92 Million JPY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 661.08 Million JPY | -13.45% |
| 2024 Q1 | 763.8 Million JPY | 1.34% |
| 2024 Q3 | 694.98 Million JPY | 5.13% |
| 2023 Q3 | 888.68 Million JPY | 16.45% |
| 2023 FY | 3.18 Billion JPY | 3.94% |
| 2023 Q4 | 753.68 Million JPY | -15.19% |
| 2023 Q2 | 763.16 Million JPY | -2.09% |
| 2023 Q1 | 779.46 Million JPY | -24.09% |
| 2022 Q4 | 1.02 Billion JPY | 22.07% |
| 2022 FY | 3.06 Billion JPY | 47.75% |
| 2022 Q2 | 614.97 Million JPY | 5.79% |
| 2022 Q1 | 581.33 Million JPY | 0.99% |
| 2022 Q3 | 841.17 Million JPY | 36.78% |
| 2021 Q2 | 510.78 Million JPY | 13.7% |
| 2021 Q1 | 449.24 Million JPY | 17.77% |
| 2021 Q3 | 538.36 Million JPY | 5.4% |
| 2021 Q4 | 575.63 Million JPY | 6.92% |
| 2021 FY | 2.07 Billion JPY | 64.74% |
| 2020 Q4 | 381.44 Million JPY | 36.54% |
| 2020 Q2 | 281.15 Million JPY | -11.3% |
| 2020 Q1 | 316.98 Million JPY | 2.2% |
| 2020 FY | 1.25 Billion JPY | 9.13% |
| 2020 Q3 | 279.36 Million JPY | -0.64% |
| 2019 FY | 1.15 Billion JPY | 31.7% |
| 2019 Q4 | 310.15 Million JPY | 0.0% |
| 2018 FY | 875.92 Million JPY | 192.05% |
| 2017 FY | 299.92 Million JPY | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 1.88 Billion JPY | -69.298% |
| PRISM BioLab Co.,LTD | 80.3 Million JPY | -3866.081% |
| GNI Group Ltd. | 22.43 Billion JPY | 85.801% |
| Linical Co., Ltd. | 3.77 Billion JPY | 15.703% |
| Trans Genic Inc. | 2.24 Billion JPY | -41.602% |
| MEDINET Co., Ltd. | 98.25 Million JPY | -3141.665% |
| Soiken Holdings Inc. | 2.48 Billion JPY | -28.305% |
| Cytori Cell Research Institute, Inc. | 1.29 Billion JPY | -146.401% |
| AnGes, Inc. | -3.06 Billion JPY | 203.905% |
| OncoTherapy Science, Inc. | -177.71 Million JPY | 1892.166% |
| Nxera Pharma Co., Ltd. | 9.66 Billion JPY | 67.043% |
| Immuno-Biological Laboratories Co., Ltd. | 517.29 Million JPY | -515.705% |
| NanoCarrier Co., Ltd. | 110.95 Million JPY | -2770.508% |
| Carna Biosciences, Inc. | 1.45 Billion JPY | -119.565% |
| CanBas Co., Ltd. | -984 Million JPY | 423.679% |
| D. Western Therapeutics Institute, Inc. | 391.69 Million JPY | -713.127% |
| RaQualia Pharma Inc. | 1.65 Billion JPY | -92.314% |
| Chiome Bioscience Inc. | 398.59 Million JPY | -699.057% |
| Kidswell Bio Corporation | 1.03 Billion JPY | -206.432% |
| PeptiDream Inc. | 17.21 Billion JPY | 81.503% |
| Oncolys BioPharma Inc. | 30.6 Million JPY | -10306.8% |
| Ribomic Inc. | -10.5 Million JPY | 30427.566% |
| SanBio Company Limited | -14.5 Million JPY | 22059.466% |
| Healios K.K. | 108 Million JPY | -2849.075% |
| BrightPath Biotherapeutics Co., Ltd. | -341 Thousand JPY | 934117.889% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -59.04 Million JPY | 5494.101% |
| Delta-Fly Pharma, Inc. | -1.51 Million JPY | 210748.214% |
| StemRIM | -44.34 Million JPY | 7281.675% |
| FunPep Company Limited | -680.28 Million JPY | 568.185% |
| Kringle Pharma, Inc. | 69.25 Million JPY | -4499.279% |
| Stella Pharma Corporation | 217.29 Million JPY | -1365.73% |
| TMS Co., Ltd. | -6.95 Million JPY | 45927.353% |
| Noile-Immune Biotech Inc. | 314.56 Million JPY | -912.523% |
| Cuorips Inc. | 9.63 Million JPY | -32970.304% |
| K Pharma,Inc. | 910 Million JPY | -250.0% |
| Takara Bio Inc. | 25.45 Billion JPY | 87.489% |
| ReproCELL Incorporated | 1.1 Billion JPY | -188.308% |
| PhoenixBio Co., Ltd. | 1.19 Billion JPY | -166.514% |
| StemCell Institute Inc. | 1.57 Billion JPY | -102.109% |
| Japan Tissue Engineering Co., Ltd. | 1.66 Billion JPY | -91.087% |
| CellSeed Inc. | 107.15 Million JPY | -2872.331% |